Raia Drogasil
Market Cap
R$43.2b
Last Updated
2021/01/21 21:59 UTC
Data Sources
Company Financials +
Executive Summary
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Raia Drogasil's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RADL3 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: RADL3's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-1.5%
RADL3
0.8%
BR Consumer Retailing
-0.7%
BR Market
1 Year Return
3.3%
RADL3
6.0%
BR Consumer Retailing
0.8%
BR Market
Return vs Industry: RADL3 underperformed the BR Consumer Retailing industry which returned 6% over the past year.
Return vs Market: RADL3 exceeded the BR Market which returned 0.8% over the past year.
Shareholder returns
| RADL3 | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.5% | 0.8% | -0.7% |
| 30 Day | 0.5% | 6.0% | 4.9% |
| 90 Day | -0.7% | 3.4% | 16.8% |
| 1 Year | 3.9%3.3% | 8.8%6.0% | 3.5%0.8% |
| 3 Year | 54.4%51.0% | 29.3%20.0% | 54.4%37.8% |
| 5 Year | 234.9%221.3% | 61.0%38.3% | 219.0%164.3% |
Long-Term Price Volatility Vs. Market
How volatile is Raia Drogasil's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
You Have To Love Raia Drogasil S.A.'s (BVMF:RADL3) Dividend4 weeks ago | Simply Wall St
Did Business Growth Power Raia Drogasil's (BVMF:RADL3) Share Price Gain of 253%?1 month ago | Simply Wall St
Is Raia Drogasil (BVMF:RADL3) A Risky Investment?Valuation
Is Raia Drogasil undervalued compared to its fair value and its price relative to the market?
102.87x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: RADL3 (R$25.51) is trading above our estimate of fair value (R$9.55)
Significantly Below Fair Value: RADL3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RADL3 is poor value based on its PE Ratio (102.9x) compared to the BR Consumer Retailing industry average (42.6x).
PE vs Market: RADL3 is poor value based on its PE Ratio (102.9x) compared to the BR market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: RADL3 is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: RADL3 is overvalued based on its PB Ratio (10.1x) compared to the BR Consumer Retailing industry average (2.6x).
Next Steps
Future Growth
How is Raia Drogasil forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
29.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RADL3's forecast earnings growth (29.9% per year) is above the savings rate (9.9%).
Earnings vs Market: RADL3's earnings (29.9% per year) are forecast to grow faster than the BR market (27.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RADL3's revenue (14.2% per year) is forecast to grow faster than the BR market (10.4% per year).
High Growth Revenue: RADL3's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RADL3's Return on Equity is forecast to be high in 3 years time (23%)
Next Steps
Past Performance
How has Raia Drogasil performed over the past 5 years?
13.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RADL3 has high quality earnings.
Growing Profit Margin: RADL3's current net profit margins (2.1%) are lower than last year (4.8%).
Past Earnings Growth Analysis
Earnings Trend: RADL3's earnings have grown by 13.2% per year over the past 5 years.
Accelerating Growth: RADL3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RADL3 had negative earnings growth (-49.1%) over the past year, making it difficult to compare to the Consumer Retailing industry average (-8.4%).
Return on Equity
High ROE: RADL3's Return on Equity (9.9%) is considered low.
Next Steps
Financial Health
How is Raia Drogasil's financial position?
Financial Position Analysis
Short Term Liabilities: RADL3's short term assets (R$6.4B) exceed its short term liabilities (R$4.2B).
Long Term Liabilities: RADL3's short term assets (R$6.4B) exceed its long term liabilities (R$4.6B).
Debt to Equity History and Analysis
Debt Level: RADL3's debt to equity ratio (41%) is considered high.
Reducing Debt: RADL3's debt to equity ratio has increased from 9.9% to 41% over the past 5 years.
Debt Coverage: RADL3's debt is well covered by operating cash flow (66.3%).
Interest Coverage: RADL3's interest payments on its debt are not well covered by EBIT (2.6x coverage).
Balance Sheet
Next Steps
Dividend
What is Raia Drogasil current dividend yield, its reliability and sustainability?
0.50%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: RADL3's dividend (0.5%) isn’t notable compared to the bottom 25% of dividend payers in the BR market (0.95%).
High Dividend: RADL3's dividend (0.5%) is low compared to the top 25% of dividend payers in the BR market (5%).
Stability and Growth of Payments
Stable Dividend: RADL3's dividend payments have been volatile in the past 10 years.
Growing Dividend: RADL3's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (47.7%), RADL3's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: RADL3's dividends in 3 years are forecast to be covered by earnings (50.4% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
19.0yrs
Average board tenure
CEO
Marcílio Pousada (55 yo)
7.5yrs
Tenure
Mr. Marcílio D'Amigo Pousada has been the Chief Executive Officer of Raia Drogasil S.A. since July 1, 2013 and serves as its Member of Executive Board. Mr. Pousada serves as the Chief Executive Officer of ...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP of Corporate Planning | no data | no data | 0% R$ 0 | |
| Independent Director | 14yrs | no data | no data | |
| Director | no data | no data | no data | |
| Director | 27yrs | no data | no data | |
| Alternate Director | no data | no data | 7.76% R$ 3.4b | |
| Alternate Director | no data | no data | no data | |
| Director | 19yrs | no data | no data | |
| Director | 27yrs | no data | 0.77% R$ 332.4m | |
| Chairman of the Board | no data | no data | 3.45% R$ 1.5b | |
| Director | 7.75yrs | no data | 1.19% R$ 514.0m | |
| Independent Director | no data | no data | no data | |
| Independent Director | no data | no data | no data |
19.0yrs
Average Tenure
Experienced Board: RADL3's board of directors are seasoned and experienced ( 19 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Raia Drogasil S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Raia Drogasil S.A.
- Ticker: RADL3
- Exchange: BOVESPA
- Founded: 1905
- Industry: Drug Retail
- Sector: Consumer Retailing
- Market Cap: R$43.230b
- Shares outstanding: 1.65b
- Website: https://www.rd.com.br
Number of Employees
Location
- Raia Drogasil S.A.
- Av. Corifeu de Azevedo Marques, 3097
- Butantã
- São Paulo
- São Paulo
- 05339-000
- Brazil
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RADL3 | BOVESPA (Bolsa de Valores de Sao Paulo) | Yes | Common Shares | BR | BRL | Nov 2008 |
| RADL.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Apr 2016 |
Biography
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. As of September 30, 2020, the company...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 21:59 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.